Skip to main content
SpringerLink
Log in

Managing a Crisis in Clinical Trials

  • Biotools
  • Published:
Bio/Technology Submit manuscript

Here is how to respond if outcomes don't match expectations

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hassler S. 1994. Bioteeh goes to trial. Bio/Technology 12: 55

    Google Scholar 

  2. See e.g., Tanouye Elyse. Is bioteeh going bust by rushing clinical trials? Wall St. J. July 21, 1994, pg. B1; Hamilton, J. Bioteeh. Bus. Wi., Sept. 26, 1994, pg. 84.

  3. In early March of this year it was announced that Synergen had reached a $28 million settlement with a class of shareholders who purchased stock between November 1991 and February 1993.

Download references

Author information

Authors and Affiliations

  1. are attorneys at Goodwin, Procter & Hoar, Exchange Place, Boston, MA, 02109

    John J. Egan III, R. Todd Cronan & Joseph L. Johnson III

Authors
  1. John J. Egan III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Todd Cronan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph L. Johnson III
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Egan, J., Cronan, R. & Johnson, J. Managing a Crisis in Clinical Trials. Nat Biotechnol 13, 559–561 (1995). https://doi.org/10.1038/nbt0695-559

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0695-559

  • Springer Nature America, Inc.

Search

Navigation